ketanserin has been researched along with ANS (Autonomic Nervous System) Diseases in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brouwer, RM | 1 |
| Wenting, GJ | 1 |
| Man in't Veld, AJ | 1 |
| Schalekamp, MA | 1 |
1 trial available for ketanserin and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
Role of alpha-adrenergic blockade in the cardiovascular actions of ketanserin: studies in patients with essential hypertension, autonomic insufficiency, and Raynaud's phenomenon.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Autonomic Nervous System Diseases; Blood Pressure; Humans | 1987 |